A. Finzi

This study investigates how temperature affects SARS-CoV-2 Spike protein affinity for ACE2, finding increased binding at low temperatures, which is mitigated by the N501Y mutation.

This study shows that non-neutralizing antibodies targeting HIV-1 envelope regions reduce mucosal infection and virus burden in humanized mice through Fc-mediated effector functions.

The paper isolates and characterizes cross-neutralizing antibodies from COVID-19 patients, identifying antibodies that neutralize both SARS-CoV-1 and SARS-CoV-2, including variants.

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.

This study tracks the decline of antibodies against the full-length SARS-CoV-2 Spike in convalescent plasma over time, showing a gradual decrease correlated with RBD-specific antibodies and days post-infection.

This study shows that IgM plays a major role in neutralizing SARS-CoV-2 in convalescent plasma, with its depletion causing the greatest loss of neutralizing activity.

This study uses smFRET to observe real-time conformational dynamics of SARS-CoV-2 spikes on virus particles, revealing multiple states and mechanisms of neutralization by antibodies and convalescent plasma.

This study compares the cooperativity of ACE2 binding to SARS-CoV-1 and SARS-CoV-2 Spike proteins, finding that SARS-CoV-2 exhibits positive cooperativity.

The paper tracks antibody levels against SARS-CoV-2 RBD in convalescent plasma donors over time, finding a decline in antibodies after ~76 days post-symptoms onset.

This study evaluates humoral responses against SARS-CoV-2 Spike in 106 infected individuals, finding persistent RBD-specific IgG and declining neutralizing activity over time.

This study shows that high serum neutralizing antibody titers from Env protein vaccination protect rhesus macaques from Tier 2 SHIV challenge, with ~1:500 ID50 titers providing over 90% protection.